免疫检查点抑制剂相关胆管炎的研究进展  

Research advances in immune checkpoint inhibitor-related cholangitis

作　　者：侯昱丞 赵洪强 董草儿 吴广东 童翾 李昂[1] 卢倩 陈虹[1] 汤睿[1] HOU Yucheng;ZHAO Hongqiang;DONG Caoer;WU Guangdong;TONG Xuan;LI Ang;LU Qian;CHEN Hong;TANG Rui(Hepatobiliary and Pancreatic Center,Tsinghua University Affiliated Beijing Tsinghua Changgung Hospital,School of Clinical Medicine,Tsinghua University,Beijing 102218,China)

机构地区：[1]清华大学附属北京清华长庚医院肝胆胰中心,清华大学临床医学院,北京102218

出　　处：《临床肝胆病杂志》2023年第2期463-468,共6页Journal of Clinical Hepatology

基　　金：国家自然科学基金(81901957)。

摘　　要：免疫检查点抑制剂开启了肿瘤治疗的新时代,而免疫治疗相关不良事件是制约其临床应用并逐渐引发关注的重要问题。肝脏是较易受累的靶器官之一。随着研究的进展,学者发现除肝细胞外,肝内外胆管也可成为免疫攻击的对象,继发被称为免疫相关胆管炎的病症。本文通过文献汇总,对免疫检查点抑制剂相关胆管炎的研究进展进行综述,旨在初步揭示其临床、病理、影像特点,为临床早期发现,规范治疗及后续研究提供线索。Immune checkpoint inhibitors(ICIs) have ushered in a new era of tumor treatment;however,immunotherapy-related adverse events are critical issues that restrict the clinical application of ICIs and have attracted wide attention.The liver is one of the target organs that is easily affected.With the progress in research,scholars have found that besides hepatocytes,intrahepatic and extrahepatic bile ducts can also be attacked by the immune system,leading to the disease known as immune-related cholangitis.This article reviews the research advances in ICI-related cholangitis by summarizing related articles,in order to preliminarily reveal its clinical,pathological,and imaging features and provide clues for early identification,standard treatment,and subsequent research.

关 键 词：免疫检查点抑制剂 免疫相关胆管炎 程序性死亡蛋白-1 

分 类 号：R575.7[医药卫生—消化系统]